Minimal residual disease in multiple myeloma: why, when, where
Dec 10, 2021 · Understand the role of MRD status in prognosis in multiple myeloma. Explore how to apply MRD testing in clinical practice and its limitations
What is minimal residual disease (MRD)? - MD Anderson Cancer Center
Jul 15, 2020 · Minimal residual disease (MRD) is common in patients with blood cancers, such as leukemia, lymphoma and multiple myeloma. But what does this mean for patients and their need for additional cancer treatment?
Minimal residual disease in multiple myeloma: current status
Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the depth of post-therapeutic ...
Minimal Residual Disease in Multiple Myeloma: Past, Present, …
Detection of MRD in multiple myeloma represents an exciting field, with strong evidence supporting its prognostic role during the entire course of the disease, and a plethora of new alternatives under constant development to identify residual tumor cells in and outside the BM.
Measurable residual disease (MRD) dynamics in multiple myeloma …
Aug 7, 2024 · Minimal residual disease (MRD) assessment is a known surrogate marker for survival in multiple myeloma (MM) and sustained MRD has become the new therapeutic objective for MM treatment [1,...
Minimal Residual Disease in Multiple Myeloma: State of the Art …
Sep 10, 2020 · MFC is widely used in clinical practice to evaluate MM MRD and the depth of complete response (CR) in the bone marrow (BM) of MM patients after therapy [17]. MFC is efficient in detecting and quantifying tumors vs. normal plasma cells (PCs) by using specific markers present on the cell surface or in the cytoplasm.
Minimal Residual Disease in Multiple Myeloma: State of the Art …
Jul 7, 2020 · Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival.
Evolving Role of MRD Status in Multiple Myeloma
4 days ago · By Caroline Helwick. November 10, 2024. The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in the clinic.
Minimal residual disease in multiple myeloma: current status
Oct 14, 2021 · Multiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the depth of post-therapeutic remission.
Minimal residual disease response-adapted therapy in newly …
Sep 27, 2023 · We present the final analysis of the MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy in patients with newly diagnosed multiple myeloma, in which MRD status is used to modulate treatment duration and cessation.